search
close_mark
pharmcetical-service-banner

Creating well-written and structured documents is crucial for drug approval and submission. Regulatory medical writing involves compiling information from clinical trials, safety reports, and other key documents to produce submission-ready materials for M2, M4, and M5 modules.

Celegence’s global medical writing specialists are experts in drug development, multiple therapeutic areas and product types. We have in-depth knowledge of regulatory, clinical, and scientific content, integrated with technical, editorial, and quality control skills. Our writers collaborate with various stakeholders, including clinical operations, data management, biostatistics, medical, and safety teams. They bring extensive industry experience from pharmaceuticals, medical devices, CROs, service providers, and academia, covering all forms of medical and scientific writing.

CMC Technical Writing Services

CMC Technical Writing Services

Publishing and Submission Services

Publishing and Submission Services

Industry Leaders Trust Celegence

Regulatory Medical Writing Services

Strategic Services

Integrated planning and execution, coordination of all writing and review activities across various domains and therapeutic areas.

End-to-End Support

Medical writing, editing, comprehensive review of regulatory and scientific documents, and responses to regulatory and health authorities.

Systematic Literature Reviews

Routine reviews for specific therapeutic and product areas.

Document Organization

Incorporating clinical and scientific results, evaluation reports, literature references, graphics, tables, and data listings.

Data Review and Input

Reviewing and providing input on medical and scientific data, including gap analyses.

Clinical Research Insight

Insight into clinical research, device/drug development processes, regulatory requirements, good clinical, and data management practices.

Publication Documents

Manuscripts, posters, presentations, and slide decks for advertising/promotional material.

Quality Focus

Timely delivery with a focus on high standards of quality.

Quality Focus

Timely delivery with a focus on high standards of quality.

Pharmacovigilance Documents

PBRER, PSURs, DSUR, PADER, PAER, SSUR, and country-specific safety reports.

Regulatory Documents

CCDS, RMP, PPI, Package Inserts/Medication Guides, USPI, SmPCs, INDs, NDAs, MAAs, and other international drug submissions, briefing documents for agency meetings.

End-to-End Support for Clinical Documentation

 

  • Protocols
  • Investigator Brochures (IBs)
  • Case Report Forms (CRFs)
  • Clinical Study Reports (Phase I to IV)
  • Informed Consent Forms (ICF)
  • Clinical and Non-Clinical Summaries
  • Safety Narratives/Summaries
  • RTQs

LEAN AUTHORING METHOD

Lean authoring offers a transformative approach to streamline submissions, reduce redundancy, and improve compliance outcomes. By emphasizing clarity and structured documentation, this method is helping organizations tackle the evolving regulatory challenges for pharmaceuticals, medical devices, and beyond.

Lean Authoring Checklist

Download now to unlock your access to the Lean Authoring Checklist and discover actionable steps to streamline your regulatory submissions.

Block Image

Medical Writing Document Types

1

Clinical Medical Writing - M2, M5


  • CSR:
  • Protocols:
  • Investigator’s Brochure:
  • Overviews:

2

Non-Clinical Medical Writing - M2, M4


  • Overviews:
  • Toxicology:
  • Mutagenicity:

Meet The Team

  • All our project leads have a Master’s degree in a relevant field
  • All have 10+ years of experience in Pharmaceutical Regulatory domain
  • Experienced supporting regulatory strategy in 50+ countries
speaker-profile

Director of Regulatory Services, Pharmaceutical

Pradeep Gangavaram

linked-in

With 20+ years of Pharmaceutical industry experience across Drug Discovery, Regulatory Affairs, and Compliance, Pradeep is a system and business process owner leading our Pharma division delivery teams. Pradeep holds a Masters degree in Biotechnology from Bangalore University. Established a Regulatory Operations team for Consumer Health business unit Spearheaded several RIM/eDMS and publishing system migrations Successfully managed xEVMPD integration into P&G Healthcare business unit Led business process harmonization and digitization activities for raw materials documentation and its compliance Co-chaired IDMP office

Read More

Read Less

speaker-profile

Head of Regulatory Affairs

Marloes van der Geer

linked-in

Marloes provides regulatory affairs consultancy and services to both big- and small-sized pharmaceutical companies, covering a wide variety of products.

Marloes holds a master in Life Sciences (Drug Innovation) from the University of Utrecht, the Netherlands. For nine years she held several positions at Hoffmann-la Roche in Switzerland, including the role of regulatory intelligence manager and regulatory policy lead for the EMEA region. Awarded DIA Leader of Tomorrow in 2016. Helped author the biosimilar guidelines across the globe.

Read More

Read Less

speaker-profile

Regulatory Affairs SME

Diede van Bladel

linked-in

Diede is a Regulatory Affairs Subject Matter Expert. She specializes in clinical trial applications and scientific advice, with a primary focus on regulatory processes within Europe, including European Medicines Agency (EMA) and Clinical Trials Information System (CTIS). With experience in Regulatory Intelligence, eCTD template development, and Module 1 documentation support – including electronic Application Forms (eAF), Product Information, and Risk Management Plan (RMP) updates – Diede brings a thorough understanding of regulatory strategies to her role. She holds a PhD in Hemato-pathology and both a Bachelor’s and Master’s degree in Biomedical Sciences. Her academic expertise, combined with her industry experience, enables her to navigate regulatory landscapes and provide guidance to clients.

Read More

Read Less

Cloud eCTD viewer and dossier management for electronic publishing and submissions

Our proprietary cloud-based dossier management solution eliminates manual steps in the exchange of regulatory dossiers. It allows you to share, view, and review eCTD, NeeS, and other dossier formats from any region and access them in any location.

The hybrid solution offers you cloud-based software as a service whilst keeping your data privately stored on-site or in a virtual private cloud.

logo

Features of Dossplorer™ eCTD Viewer:


  • Automated import of dossiers and sequences
  • SaaS solution
  • Intuitive search functionality
  • Explore holistic views across dossiers worldwide
  • Personalized navigation tree utilizing metadata already present in dossiers
  • Multiple dossier formats supported
  • Advanced restrictions
  • Integrated eCTD viewer with Single Sign-on solutions
infograminc

Intuitive MS Word templates for eCTD-ready documents without software installation

DosscriberTM helps stand-alone regulatory documents for, amongst others, NDA/BLA, IND, NDS, MAA, CTA, PIP, scientific advice, and briefing packages.

With consistent document structure, naming, and eCTD-readiness, Dosscriber™ templates facilitate repurposing documents across countries, products, and dossier types – without rework.

logo

Features of eCTD Document Templates:


  • Embedded fonts and paragraph styles
  • Structured information in tabular formats
  • Multiple options for granularity
  • Prefilled document headers, footers, and properties
  • Regulatory (ICH) guidance and experience
  • MS Word document templates with content control boxes

End-To-End Publishing & Submission Services

  • Icon

    Investigational New Drug Application (INDA)

    Expand
  • Icon

    Submitted to CDER.

  • Icon

    Required after pre-clinical studies but before initiating a clinical trial.

  • Icon

    Request for FDA authorization to administer an investigational drug to humans.

  • Icon

    Investigator IND: Submitted by Physician.

  • Icon

    Emergency IND: to authorize use of an experimental drug in an emergency situation.

  • Icon

    Treatment IND: submitted for experimental drugs showing promise in clinical testing for serious or immediate life-threatening.

  • Icon

    Abbreviated New Drug Application (ANDA)

    Expand
  • Icon

    Submitted for the review and approval of a generic drug.

  • Icon

    Termed abbreviated because this submission is generally not required to include pre-clinical and clinical data.

  • Icon

    Drug must demonstrate therapeutic equivalence to a previously approved “reference listed drug”.

  • Icon

    Drug must demonstrate therapeutic equivalence to a previously approved “reference listed drug”.

  • Icon

    Biological License Application (NDA)

    Expand
  • Icon

    Submitted to CBER.

  • Icon

    Submitted for vaccines, blood and blood components, somatic cells, gene therapy, and other biological drug products.

  • Icon

    New Drug Application (NDA)

    Expand
  • Icon

    Regulatory procedure through which sponsors propose FDA to approve a new pharmaceutical drug.

  • Icon

    Must establish the safety and efficacy of the drug in its proposed use.

  • Icon

    Manufacturing methods and controls adequately preserves the drug’s strength, quality and purity.

View Publishing & Submission Services

Your Trusted Partner for Regulatory Writing

Caroline Mandret

Regulatory Operations Manager,

We are very satisfied with our collaboration with Celegence. For several years now, we have been relying on them for the XEVMPD submission of our data. On the strength of this positive experience, we have extended their scope of intervention to include data entry in LifeSphere and are now embarking on a new project to enrich our IDMP data in this same solution. Their in-depth expertise and perfect understanding of regulatory requirements, combined with a pragmatic, results-oriented approach, have significantly enhanced the quality and efficiency of our data management processes. What sets Celegence apart is their ability to quickly identify our specific needs and propose tailor-made solutions, which is a key factor in our success. Their structured and proactive support enables us to reach important milestones with serenity and clarity. As we continue to transform our regulatory operations, choosing Celegence as our long-term partner was a natural strategic decision. We look forward to continuing this fruitful collaboration

Jason Mattis

President,

I have been working with Celegence for several years and very much appreciate their partnership on so many levels. Celegence has very strong CMC experience and not only provided us much needed consultant services, but they also worked with us to utilize and leverage industry-disrupting digital solutions, Dossplorer™ and CAPTIS®. These tools have changed how we access and use our own data. Dossplorer™ (a dossier viewing tool) was upgraded with industry leading features such as translation, a goggle-like power search, document compare and many others that drastically reduce the time it takes to perform change impact assessments, document comparisons, translation and search within non-English documents and the ability to upload many other critical Health Authority documents keeping our dossiers fully compliant and current. Since Dossplorer could be used by anyone in Kenvue, it gave this power to all our stakeholders and business partners as well. CAPTIS® (an AI enabled technical/medical writing tool) was piloted with the CMC team in Kenvue to see where we could leverage using AI to author Module 3 quality submission ready documents. The Celegence team was able to automate technical writing for 5+ of the most frequently written Module 3 quality submission documents to streamline our life cycle management workload and resources. The documents Celegence provided using their AI tool were shown to be remarkably reliable when compared to manual preparation. This pilot showed the art of possible. We achieved great things with Celegence and appreciate their collaboration and expertise

Ben Dowd

Senior Manager, Regulatory Affairs,

Working with Celegence on our publishing and submission activities has delivered significant value. Their client-focused approach, combined with deep regulatory knowledge and smart tools like Dossplorer, enabled real-time collaboration and faster decision-making. Thanks to their support, we were able to meet tight deadlines without compromising quality—cutting publishing time significantly for major submissions and reducing rework substantially. Celegence’s professionalism, responsiveness, and commitment to our success have made them an essential extension of our internal team. We’re confident that with Celegence, we have the right partner to support our regulatory operations moving forward.

Bimpe Shitta-Bey

Regulatory Strategy Lead,

Partnering with Celegence for our publishing and submissions has been a game-changer. Their combination of knowledgeable, client-focused experts and technology-enabled services has dramatically improved our efficiency. The use of Dossplorer’s real-time review and commenting capabilities played a pivotal role in meeting tight submission deadlines. From collaborative document preparation to seamless eCTD publishing, their tools and expertise have directly accelerated our submission and approval timelines. With Celegence’s support, we cut our publishing time in half, minimized rework, and consistently met aggressive timelines. Their responsiveness and commitment to excellence make them one of our most reliable business partners. I would never hesitate to recommend their services.

Ron Celeste

President,

Celegence has consistently demonstrated the value of their tech-enabled services in improving efficiency and compliance. The use of eCTD templates saves significant hours of document readiness and rework – streamlining the preparation and reducing publishing timelines. These templates consistently deliver hard returns on investment, helping organizations save time and resources. Additionally, the use of Dossplorer’s real-time review and comments feature was instrumental in meeting submission timelines, which otherwise might not have been achievable. From document collaboration to seamless publishing, Celegence’s tools and expertise are driving measurable time-to-market improvements and enabling success where it matters most. Celegence’s tech-enabled services consistently deliver immediate value. Qdossier supported by eCTD submission experts, allowed us to cut our publishing time for a full New Drug Application in half. Rework was minimized, allowing us to meet aggressive timelines. Customer service responsiveness is top-notch. Celegence is the best business partner we’ve had in our 25 years. We managed to publish a full NDA with a very aggressive timeline; we have successfully submitted it to the FDA just 12 working days after we started publishing the first set of documents. A total of 645 PDF files have been published, 450 dataset files have been included, and almost 2000 hyperlinks have been created in this dossier. The submission itself has been reviewed by the customer directly in Dossplorer, which was a key solution with this challenging timeline

Contact Us Today

From document publishing automation to eCTD submissions and beyond, Celegence is your trusted partner for regulatory affairs excellence. Contact us to learn how we can help you achieve your compliance goals efficiently and cost-effectively.

"*" indicates required fields